When the federal government reversed course last month, deciding not to regulate many genetic tests, one big winner was Proove Biosciences, a Southern California company that markets an unproven “opioid risk” test.
Proove claims its test can predict, with 93 percent accuracy, which patients will become addicted to or misuse prescribed opioid pain pills. That’s been an irresistible sales pitch for many physicians, who struggle to treat pain patients compassionately but fear adding to the national epidemic of opioid addiction. The Irvine, Calif., company has recruited 400 doctors, who have used the test to guide their treatment of more than 100,000 patients in the last five years.
[For more of this story, written by Charles Piller, go to https://www.statnews.com/2016/...ve-opioid-risk-test/]
Comments (0)